Sergio Adrian Ocampo-Ortega

Dr. Sergio Adrian Ocampo-Ortega

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Current Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
CBCitlali Margarita Blancas-Napoles
Citlali Margarita Blancas-Napoles
SCSandra Edith Cabrera-Becerra
Sandra Edith Cabrera-Becerra
VSVivany Sierra
Vivany Sierra
SOSergio Adrian Ocampo-Ortega
Sergio Adrian Ocampo-Ortega
VGVanessa Giselle Garcia-Rubio
Vanessa Giselle Garcia-Rubio
SVSantiago Villafaña
Santiago Villafaña
Aims: The aim of this study was to develop a possible treatment for pulmonary arterial hypertension. Background: Pulmonary arterial hypertension (PAH) is a rare disease characterised by a pulmonary arterial pressure greater than 20 mmHg. One of the factors that contribute to PAH is an increase in the production of endothelin-1, a polypeptide that increases vascular resistance in the pulmonary arteries, leading to increased pulmonary arterial pressure and right ventricular hypertrophy. Objective: The objective of this study was to design, synthesize, and evaluate two siRNAs directed against endothelin-1 in a rat model of PAH induced with monocrotaline. Methods: Wistar rats were administered monocrotaline (60 mg/kg) to induce a PAH model. Following two weeks of PAH evolution, the siRNAs were administered, and after two weeks, right ventricular hypertrophy was evaluated using the RV/LV+S ratio, blood pressure, weight, and relative expression of ECE-1 (Endothelin-converting enzyme-1) mRNA (messenger RNA) by RT-PCR (real-time PCR). Results: The monocrotaline group showed an increase in the hypertrophy index and in ECE-1 mRNA, as well as a significant decrease in weight compared to the control group, while in the monocrotaline + siRNA group, a significant decrease was observed in the relative expression of ECE-1 mRNA, as well as in right ventricular hypertrophy. Conclusions: Based on the above information, we conclude that the administration of siRNAs directed to ECE-1 decreases the damage associated with PAH.

4 February 2024 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
SOSergio Adrian Ocampo-Ortega
Sergio Adrian Ocampo-Ortega
SCSandra Edith Cabrera-Becerra
Sandra Edith Cabrera-Becerra
VSVivany Sierra
Vivany Sierra
VGVanessa Giselle García-Rubio
Vanessa Giselle García-Rubio
CBCitlali Margarita Blancas-Napoles
Citlali Margarita Blancas-Napoles
SVSantiago Villafaña
Santiago Villafaña
Chronic obstructive pulmonary disease (COPD), characterised by persistent airflow limitation during breathing, is considered to be the third leading cause of death worldwide. Among the mechanisms involved in this pathology is the excessive generation of neutrophil extracellular traps (NETs), which can induce an unwanted inflammatory response. These traps have been reported to be generated by the enzyme peptidyl arginine deiminase 4 (PAD4). The aim of this work is therefore to evaluate the effect of the administration of a siRNA targeting PAD4 on lung damage in a COPD animal model. Wistar rats weighing 300–350 g were administered cadmium chloride (5 mg/kg i.p.) every 24 h. Then, following one week of the administration of cadmium chloride, the PAD4-targeted siRNA was administered, and at the second week, lung function was measured, as were lung and heart weights, as well as PAD4 expression by RT-PCR. Our results showed that cadmium administration generated a COPD model, which increased PAD4 expression and decreased lung and heart weights and respiratory function. SiRNA administration partially reversed the changes associated with the COPD model. In conclusion, our results suggest that administration of an siRNA targeting PAD4 could improve respiratory function by decreasing lung and heart damage.

15 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
VSVivany Sierra
Vivany Sierra
CBCitlali Margarita Blancas-Napoles
Citlali Margarita Blancas-Napoles
ASAina Daniela Sánchez-Maldonado
Aina Daniela Sánchez-Maldonado
IMIndira Medina
Indira Medina
RRRodrigo Romero-Nava
Rodrigo Romero-Nava
SVSantiago Villafaña
Santiago Villafaña
Background/Objectives: Neuropilin-1 (NRP1) is a key co-receptor for SARS-CoV-2, complementing the ACE2 receptor. Several investigations have documented highly conserved sequences in this receptor, supporting the implication of NRP1 as a key mediator in SARS-CoV-2 cellular entry mechanisms. Methods: To investigate this hypothesis, we examined 104,737 SARS-CoV-2 genome fastas from GISAID genomic data, corresponding to isolates collected between 2020 and 2025 in Mexico. Specifically, we focused on the RRAR motif, a known furin-binding site for NRP-1 and the binding site for ACE2 with the spike protein. Our analysis revealed high conservation (>98%) of the RRAR domain compared to a rapidly diminishing ACE2-binding domain. A complementary analysis, using Data from Gene Expression Omnibus (GEO, GSE150316), showed that NRP1 expression in lung tissue remains relatively stable, whereas ACE2 displayed high inter-individual variability and lower abundance compared to NRP1. Based on this evidence, we designed two humans–rats NRP1 siRNAs that were tested in vivo using a melittin-induced lung injury model. Results: The RT-PCR assays confirmed an effective NRP1 knockdown, and the siRNA-treated group showed a significant reduction in the lesions severity. These findings highlight NRP1 as a stable and relevant therapeutic target and suggest the protective potential of siRNA-mediated gene silencing. Conclusions: The evidence presented here supports the rational design of NRP1-directed therapies for multiple circulating SARS-CoV-2 variants in Mexico.

8 November 2023 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
VGVanessa Giselle Garcia-Rubio
Vanessa Giselle Garcia-Rubio
SCSandra Edith Cabrera-Becerra
Sandra Edith Cabrera-Becerra
SOSergio Adrian Ocampo-Ortega
Sergio Adrian Ocampo-Ortega
CBCitlali Margarita Blancas-Napoles
Citlali Margarita Blancas-Napoles
VSVivany Sierra
Vivany Sierra
SVSantiago Villafaña
Santiago Villafaña
Diabetes mellitus is a metabolic disease that can produce different alterations such as endothelial dysfunction, which is defined as a decrease in the vasodilator responses of the mechanisms involved such as the nitric oxide (NO) pathway. The overexpression of PDE5A has been reported in diabetes, which causes an increase in the hydrolysis of cGMP and a decrease in the NO pathway. For this reason, the aim of this study was to evaluate whether siRNAs targeting PDE5A can reduce the endothelial dysfunction associated with diabetes. We used male Wistar rats (200–250 g) that were administered streptozotocin (STZ) (60 mg/kg i.p) to induce diabetes. Two weeks after STZ administration, the siRNAs or vehicle were administered and then, at 4 weeks, dose–response curves to acetylcholine were performed and PDE5A mRNA levels were measured by RT-PCR. siRNAs were designed by the bioinformatic analysis of human–rat FASTA sequences and synthesised in the Mermade-8 equipment. Our results showed that 4 weeks of diabetes produces a decrease in the vasodilator responses to acetylcholine and an increase in the expression of PDE5A mRNA, while the administration of siRNAs partially restores the vasodilator response and decreases PDE5A expression. We conclude that the administration of siRNAs targeting PDE5A partially reverts the endothelial impairment associated with diabetes.

9 September 2026 in Hygiene
Verified
Journal Article
Open access
PDF file
AIAlelí Julieta Izquierdo-Vega
Alelí Julieta Izquierdo-Vega
MSManuel Sanchez
Manuel Sanchez
EMEduardo Madrigal-Santillán
Eduardo Madrigal-Santillán
JIJeannett Izquierdo
Jeannett Izquierdo
SOSergio Adrian Ocampo-Ortega
Sergio Adrian Ocampo-Ortega
AHAraceli Hernandez-Zavala
Araceli Hernandez-Zavala
Background: Histone deacetylase inhibitors (HDACis) have been suggested as novel pharmacological agents for various clinical conditions, including cancer and neurodegenerative, inflammatory, autoimmune, and metabolic diseases. Periodontitis is a complex, multifactorial disease characterised by chronic inflammation, a dysbiotic microbiota, and the degradation of tooth-supporting tissues. It is influenced by factors such as immune capacity, genetic and epigenetic changes, lifestyle, and comorbidities. Objective: This systematic review with narrative synthesis examines the therapeutic potential of HDACis in the management of periodontitis. Method: The PubMed, ScienceDirect, and Web of Science databases were comprehensively searched to identify relevant articles published between 2000 and 2026. The systematic review is reported according to the 2020 PRISMA guidelines. Results: HDACis consistently attenuated periodontal inflammation, reduced alveolar bone loss, and inhibited osteoclast differentiation and activity by downregulating proinflammatory cytokines and osteoclastogenic markers. Trichostatin A, MS-275, and valproic acid were the most extensively investigated compounds. Conclusion: Overall, the findings indicate that HDAC inhibition may have therapeutic potential, although substantial methodological heterogeneity and limited translational evidence precluded conclusions regarding clinical efficacy.

4 December 2024 in Life
Verified
Journal Article
Open access
PDF file
SOSergio Adrian Ocampo-Ortega
Sergio Adrian Ocampo-Ortega
VSVivany Sierra
Vivany Sierra
CBCitlali Margarita Blancas-Napoles
Citlali Margarita Blancas-Napoles
AGAsdrúbal González-Carteño
Asdrúbal González-Carteño
EJElvia Mera Jiménez
Elvia Mera Jiménez
SVSantiago Villafaña
Santiago Villafaña
Huntington’s disease is a genetic disorder characterized by progressive neuronal cell damage in some areas of the brain; symptoms are commonly associated with chorea, rigidity and dystonia. The symptoms in Huntington’s Disease are caused by a pathological increase in the number of Cytokine-Adenine-Guanine (CAG) repeats on the first exon of the Huntingtin gene, which causes a protein to have an excessive number of glutamine residues; this alteration leads to a change in the protein’s conformation and function. Therefore, the purpose of this work was to design, synthesize and evaluate an antisense oligonucleotide (ASO; 95 nucleotides) HTT 90-5 directed to the Huntingtin CAG repeats in primary leukocyte culture cells from a patient with Huntington’s Disease; approximately 500,000 leukocytes per well extracted from venous blood were used, to which 100 pMol of ASO were administered, and the expression of Huntingtin was subsequently evaluated at 72 h by RT-PCR. Our results showed that the administration of the HTT 90-5 antisense decreased the expression of Huntingtin mRNA in the primary culture leukocyte cells from our patient. These results suggest that the use of long antisense targeting the CAG Huntingtin cluster may be an option to decrease the expression of Huntingtin and probably could be adjusted depending on the number of CAG repeats in the cluster.